Acid suppression in healthy subjects following lansoprazole or pantoprazole

J. Q. Huang, D. R. Goldwater, A. B.R. Thomson, S. A. Appelman, Subbaramiah Sridhar, C. F. James, Y. L. Chiu, B. L. Pilmer, R. G. Keith, R. H. Hunt

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Aim: To compare the effect of lansoprazole, 30 mg once daily, with that of pantoprazole, 40 mg once daily, for the inhibition of gastric acid secretion. Methods: Two randomized, single-blind, two-way, crossover studies were conducted in 74 healthy male volunteers. Lansoprazole, 30 mg, or pantoprazole, 40 mg. was administered once daily for five consecutive days with at least a 2-week washout period between regimens. Ambulatory 24-h intragastric pH was recorded at baseline and on days 1 and 5 of each crossover treatment period. Results: On day 1 in both studies, lansoprazole, 30 mg, produced significantly higher mean 24-h intragastric pH values when compared to pantoprazole, 40 mg (3.78 vs. 3.08. P<0.001, and 3.97 vs. 3.20, P < 0.001, in the first and second studies, respectively). In both studies, lansoprazole, 30 mg, produced significantly greater proportions of time that the intragastric pH was above 3, 4 and 5 when compared with pantoprazole, 40 mg (P < 0.005 in all comparisons). By treatment day 5 in the first study, lansoprazole. 30 mg, continued to produce a higher mean 24-h intragastric pH (4.15 vs. 3.91, P = 0.014) and a significantly greater percentage of time that the intragastric pH was above 4 (63% vs. 56%, P = 0.017) and 5 (41% vs. 30%, P < 0.001) when compared with pantoprazole, 40 mg. In the second study, the effects on intragastric pH were comparable between the two treatment groups. Headache was the most commonly reported adverse experience (nine lansoprazole-treated subjects, seven in the first study and two in the second study: six pantoprazole-treated subjects, five in the first study and one in the second study). Conclusions: Lansoprazole, 30 mg once daily, produces a faster onset and greater degree of acid inhibition than pantoprazole. 40 mg once daily. The implications for these differences on symptom relief and healing of erosive oesophagitis should be explored.

Original languageEnglish (US)
Pages (from-to)425-433
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number3
DOIs
StatePublished - Mar 21 2002
Externally publishedYes

Fingerprint

Lansoprazole
Healthy Volunteers
Acids
Esophagitis
Gastric Acid
pantoprazole
Cross-Over Studies
Headache
Therapeutics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

Huang, J. Q., Goldwater, D. R., Thomson, A. B. R., Appelman, S. A., Sridhar, S., James, C. F., ... Hunt, R. H. (2002). Acid suppression in healthy subjects following lansoprazole or pantoprazole. Alimentary Pharmacology and Therapeutics, 16(3), 425-433. https://doi.org/10.1046/j.1365-2036.2002.01168.x

Acid suppression in healthy subjects following lansoprazole or pantoprazole. / Huang, J. Q.; Goldwater, D. R.; Thomson, A. B.R.; Appelman, S. A.; Sridhar, Subbaramiah; James, C. F.; Chiu, Y. L.; Pilmer, B. L.; Keith, R. G.; Hunt, R. H.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 3, 21.03.2002, p. 425-433.

Research output: Contribution to journalArticle

Huang, JQ, Goldwater, DR, Thomson, ABR, Appelman, SA, Sridhar, S, James, CF, Chiu, YL, Pilmer, BL, Keith, RG & Hunt, RH 2002, 'Acid suppression in healthy subjects following lansoprazole or pantoprazole', Alimentary Pharmacology and Therapeutics, vol. 16, no. 3, pp. 425-433. https://doi.org/10.1046/j.1365-2036.2002.01168.x
Huang, J. Q. ; Goldwater, D. R. ; Thomson, A. B.R. ; Appelman, S. A. ; Sridhar, Subbaramiah ; James, C. F. ; Chiu, Y. L. ; Pilmer, B. L. ; Keith, R. G. ; Hunt, R. H. / Acid suppression in healthy subjects following lansoprazole or pantoprazole. In: Alimentary Pharmacology and Therapeutics. 2002 ; Vol. 16, No. 3. pp. 425-433.
@article{f9f0caf982044e5cba6764fc2f8c72c4,
title = "Acid suppression in healthy subjects following lansoprazole or pantoprazole",
abstract = "Aim: To compare the effect of lansoprazole, 30 mg once daily, with that of pantoprazole, 40 mg once daily, for the inhibition of gastric acid secretion. Methods: Two randomized, single-blind, two-way, crossover studies were conducted in 74 healthy male volunteers. Lansoprazole, 30 mg, or pantoprazole, 40 mg. was administered once daily for five consecutive days with at least a 2-week washout period between regimens. Ambulatory 24-h intragastric pH was recorded at baseline and on days 1 and 5 of each crossover treatment period. Results: On day 1 in both studies, lansoprazole, 30 mg, produced significantly higher mean 24-h intragastric pH values when compared to pantoprazole, 40 mg (3.78 vs. 3.08. P<0.001, and 3.97 vs. 3.20, P < 0.001, in the first and second studies, respectively). In both studies, lansoprazole, 30 mg, produced significantly greater proportions of time that the intragastric pH was above 3, 4 and 5 when compared with pantoprazole, 40 mg (P < 0.005 in all comparisons). By treatment day 5 in the first study, lansoprazole. 30 mg, continued to produce a higher mean 24-h intragastric pH (4.15 vs. 3.91, P = 0.014) and a significantly greater percentage of time that the intragastric pH was above 4 (63{\%} vs. 56{\%}, P = 0.017) and 5 (41{\%} vs. 30{\%}, P < 0.001) when compared with pantoprazole, 40 mg. In the second study, the effects on intragastric pH were comparable between the two treatment groups. Headache was the most commonly reported adverse experience (nine lansoprazole-treated subjects, seven in the first study and two in the second study: six pantoprazole-treated subjects, five in the first study and one in the second study). Conclusions: Lansoprazole, 30 mg once daily, produces a faster onset and greater degree of acid inhibition than pantoprazole. 40 mg once daily. The implications for these differences on symptom relief and healing of erosive oesophagitis should be explored.",
author = "Huang, {J. Q.} and Goldwater, {D. R.} and Thomson, {A. B.R.} and Appelman, {S. A.} and Subbaramiah Sridhar and James, {C. F.} and Chiu, {Y. L.} and Pilmer, {B. L.} and Keith, {R. G.} and Hunt, {R. H.}",
year = "2002",
month = "3",
day = "21",
doi = "10.1046/j.1365-2036.2002.01168.x",
language = "English (US)",
volume = "16",
pages = "425--433",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Acid suppression in healthy subjects following lansoprazole or pantoprazole

AU - Huang, J. Q.

AU - Goldwater, D. R.

AU - Thomson, A. B.R.

AU - Appelman, S. A.

AU - Sridhar, Subbaramiah

AU - James, C. F.

AU - Chiu, Y. L.

AU - Pilmer, B. L.

AU - Keith, R. G.

AU - Hunt, R. H.

PY - 2002/3/21

Y1 - 2002/3/21

N2 - Aim: To compare the effect of lansoprazole, 30 mg once daily, with that of pantoprazole, 40 mg once daily, for the inhibition of gastric acid secretion. Methods: Two randomized, single-blind, two-way, crossover studies were conducted in 74 healthy male volunteers. Lansoprazole, 30 mg, or pantoprazole, 40 mg. was administered once daily for five consecutive days with at least a 2-week washout period between regimens. Ambulatory 24-h intragastric pH was recorded at baseline and on days 1 and 5 of each crossover treatment period. Results: On day 1 in both studies, lansoprazole, 30 mg, produced significantly higher mean 24-h intragastric pH values when compared to pantoprazole, 40 mg (3.78 vs. 3.08. P<0.001, and 3.97 vs. 3.20, P < 0.001, in the first and second studies, respectively). In both studies, lansoprazole, 30 mg, produced significantly greater proportions of time that the intragastric pH was above 3, 4 and 5 when compared with pantoprazole, 40 mg (P < 0.005 in all comparisons). By treatment day 5 in the first study, lansoprazole. 30 mg, continued to produce a higher mean 24-h intragastric pH (4.15 vs. 3.91, P = 0.014) and a significantly greater percentage of time that the intragastric pH was above 4 (63% vs. 56%, P = 0.017) and 5 (41% vs. 30%, P < 0.001) when compared with pantoprazole, 40 mg. In the second study, the effects on intragastric pH were comparable between the two treatment groups. Headache was the most commonly reported adverse experience (nine lansoprazole-treated subjects, seven in the first study and two in the second study: six pantoprazole-treated subjects, five in the first study and one in the second study). Conclusions: Lansoprazole, 30 mg once daily, produces a faster onset and greater degree of acid inhibition than pantoprazole. 40 mg once daily. The implications for these differences on symptom relief and healing of erosive oesophagitis should be explored.

AB - Aim: To compare the effect of lansoprazole, 30 mg once daily, with that of pantoprazole, 40 mg once daily, for the inhibition of gastric acid secretion. Methods: Two randomized, single-blind, two-way, crossover studies were conducted in 74 healthy male volunteers. Lansoprazole, 30 mg, or pantoprazole, 40 mg. was administered once daily for five consecutive days with at least a 2-week washout period between regimens. Ambulatory 24-h intragastric pH was recorded at baseline and on days 1 and 5 of each crossover treatment period. Results: On day 1 in both studies, lansoprazole, 30 mg, produced significantly higher mean 24-h intragastric pH values when compared to pantoprazole, 40 mg (3.78 vs. 3.08. P<0.001, and 3.97 vs. 3.20, P < 0.001, in the first and second studies, respectively). In both studies, lansoprazole, 30 mg, produced significantly greater proportions of time that the intragastric pH was above 3, 4 and 5 when compared with pantoprazole, 40 mg (P < 0.005 in all comparisons). By treatment day 5 in the first study, lansoprazole. 30 mg, continued to produce a higher mean 24-h intragastric pH (4.15 vs. 3.91, P = 0.014) and a significantly greater percentage of time that the intragastric pH was above 4 (63% vs. 56%, P = 0.017) and 5 (41% vs. 30%, P < 0.001) when compared with pantoprazole, 40 mg. In the second study, the effects on intragastric pH were comparable between the two treatment groups. Headache was the most commonly reported adverse experience (nine lansoprazole-treated subjects, seven in the first study and two in the second study: six pantoprazole-treated subjects, five in the first study and one in the second study). Conclusions: Lansoprazole, 30 mg once daily, produces a faster onset and greater degree of acid inhibition than pantoprazole. 40 mg once daily. The implications for these differences on symptom relief and healing of erosive oesophagitis should be explored.

UR - http://www.scopus.com/inward/record.url?scp=0036191745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036191745&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01168.x

DO - 10.1046/j.1365-2036.2002.01168.x

M3 - Article

VL - 16

SP - 425

EP - 433

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -